trial
as of 2026-07-01Proof of Concept Study of Cognitive Improvement in Patients With Schizophrenia
NCTId NCT00528905
at a glance
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Completed
Enrollment
400 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2007-08
Primary completion
2008-10
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Drugs
Sponsors
AstraZenecaLead Sponsor
Investigators
1
Larry Rodichok, MDStudy Director
Sites
80 total
Little Rock, United StatesAnaheim, United StatesCerritos, United StatesCosta Mesa, United StatesEscondido, United StatesGarden Grove, United StatesLong Beach, United StatesLos Angeles, United StatesOceanside, United StatesPasadena, United StatesPico Rivera, United StatesSan Diego, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
400
Phase
PHASE2
Primary Completion Date
2008-10
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator
person